ASH Annual Meeting and Exposition | Conference

High Response Rates Seen With CAR T-Cell Therapies for NHL

December 7th 2015

Updated findings from early stage clinical trials exploring chimeric antigen receptor-modified T-cell therapies continue to highlight the effectiveness of these approaches for patients with non-Hodgkin lymphoma.

Adding Rituximab to Chemo Boosts Survival in Subgroup of ALL Patients

December 7th 2015

Two-year event-free survival increased from 52% with conventional therapy to 65% with the addition of rituximab among patients with newly diagnosed, CD20-positive Philadelphia (Ph)-chromosome negative B-cell precursor acute lymphoblastic leukemia, according to results from a phase III trial.

Midostaurin Shows Rare Survival Improvement in FLT3-Mutated AML

December 7th 2015

Patients with FLT3-mutated acute myeloid leukemia lived significantly longer when treated with the multikinase inhibitor midostaurin compared with placebo.

Dr. Harrison on 5-Year Follow-Up Data on Ruxolitinib in Patients With Myelofibrosis

December 6th 2015

Claire Harrison, MD, deputy clinical director of Cancer and Hematology, Guy's and St. Thomas' NHS, discusses 5-year follow-up data examining ruxolitinib in patients with myelofibrosis.

Venetoclax Sparks High Response Rate in Poor-Risk CLL Subtype

December 6th 2015

Venetoclax, demonstrated an overall response rate of nearly 80% among patients with chronic lymphocytic leukemia harboring the chromosome 17p deletion.

Frontline Ibrutinib Significantly Improves Survival in CLL

December 6th 2015

Ibrutinib reduced the risk of death by 84% versus chlorambucil in treatment-naÃ¯ve elderly patients with chronic lymphocytic leukemia.

Eltrombopag Improves Response Rates in Severe Aplastic Anemia

December 6th 2015

More than a third of patients with severe aplastic anemia achieved hematologic responses lasting at least 6 months with the addition of the oral thrombopoietin inhibitor eltrombopag to conventional immunosuppressive therapy.

Daratumumab Combo Sparks 81% Response Rate in Myeloma

December 6th 2015

The addition of daratumumab to a standard multiple myeloma regimen generated responses in 81% of patients with relapsed or refractory disease that were "rapid, deep, and durable" without introducing any new safety concerns.

Dr. Kumar on Tourmaline-MM1 Study for Multiple Myeloma

December 6th 2015

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the phase III Tourmaline-MM1 study, which compared the efficacy of the addition of ixazomib to lenalidomide and dexamethasone with lenalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Idelalisib Triplet Highly Effective for Relapsed/Refractory CLL

December 6th 2015

The addition of idelalisib to bendamustine and rituximab (BR) reduced the risk of progression or death by 67% compared with BR alone for patients with relapsed/refractory chronic lymphocytic leukemia.

Oral Ixazomib Triplet Improves PFS in Myeloma

December 6th 2015

An all orally administered treatment regimen containing ixazomib, lenalidomide, and dexamethasone showed a 5.9-month improvement in progression-free survival compared with lenalidomide and dexamethasone alone for patients with relapsed/refractory multiple myeloma.

Dr. Steensma on Midostaurin for Patients With AML

December 6th 2015

David P. Steensma, MD, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses a phase III study comparing midostaurin with placebo in combination with daunorubicin cytarabine induction, high-dose cytarabine consolidation, and as maintenance therapy in newly diagnosed patients with acute myeloid leukemia (AML) with FLT3 mutations.

Study Suggests Role for CAR Therapy After Transplant in Advanced B-cell Cancers

December 5th 2015

Gene therapy has the potential to deliver long-lasting remissions for patients with advanced B-cell malignancies who already have undergone an allogeneic hematopoietic stem cell transplant.

CAR T-Cell Infusion Leads to Eradication of Myeloma

December 5th 2015

Genetically engineered T cells eradicated multiple myeloma cells in a patient with advanced disease, suggesting the potential to cure the condition.

Ruxolitinib Continues to Impress in Long-Term Myelofibrosis Follow-Up

December 5th 2015

Ruxolitinib continues to demonstrate sustained benefits for patients with myelofribrosis in a 5-year follow-up of the phase III COMFORT-II study.

Ixazomib, Cyclophosphamide Combo Effective for Newly Diagnosed Myeloma

December 5th 2015

An all-oral triplet therapy of ixazomib, cyclophosphamide, and dexamethasone demonstrated promising early response rates in elderly patients with newly diagnosed multiple myeloma.

Durable Daratumumab Activity Highlighted in Combined Myeloma Analysis

December 5th 2015

Treatment with the CD38 monoclonal antibody daratumumab demonstrated a 31% overall response rate as monotherapy for patients with heavily pretreated multiple myeloma.

Dr. Young on Eltrombopag Added to Immunosuppression for Patients With Aplastic Anemia

December 5th 2015

Neal Young, MD, senior investigator, Cell Biology Section, National Heart, Lung, and Blood Institute, National Institute of Health, discusses a study that examined the efficacy of eltrombopag when added to standard immunosuppression for patients with aplastic anemia.

Benefits of Elotuzumab Sustained in 3-Year Myeloma Data

December 5th 2015

The combination of elotuzumab, lenalidomide, and dexamethasone showed sustained improvements in progression-free survival and overall survival for patients with relapsed/refractory multiple myeloma.

Bortezomib Triplet Therapy New Standard of Care for Untreated Multiple Myeloma

December 5th 2015

Induction therapy with a triplet of bortezomib, lenalidomide, and dexamethasone significantly improved progression-free survival and overall survival compared with lenalidomide and dexamethasone alone for patients with untreated multiple myeloma.